AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.27) by 33.33 percent. This is a 14.29 percent increase over losses of $(0.21) per share from the same period last year.